logo-loader
viewGenedrive PLC

Notice of AGM and Change of Auditors

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .al{size:595.45pt 841.7pt;margin:36.0pt 36.0pt 36.0pt 36.0pt;}div.al{}p.bv{margin-top:10.0pt;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-indent: 0cm}p.bw{margin-top:0cm;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-indent: 0cm}p.bx{margin-top:0cm;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: center; text-indent: 0cm}p.by{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bs{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bz{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bq{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:normal} span.bo{color:black}span.aa{}span.cb{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}span.cc{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}p.cd{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph}span.ce{font-size:10.0pt; font-family:"Arial","sans-serif";color:black}span.cf{font-size:10.0pt;font-family:"Arial","sans-serif"}span.bh{font-size:10.0pt;font-family: "Arial","sans-serif"}span.af{}span.q{font-family:"Calibri","sans-serif";color:black;} table.cg{width:18.0cm;margin-left:-5.4pt;border-collapse:collapse}td.be{width:272.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.ch{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.ci{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}td.bb{width:216.15pt;padding:0cm 5.4pt 0cm 5.4pt}p.cj{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right}span.bd{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.ck{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.cl{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.cm{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} span.cn{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.co{margin-top:10.0pt;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-indent: 0cm}p.cp{margin-top:0cm;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin: 0cm; margin-bottom: .0001pt; text-align: right; text-indent: 0cm}p.cq{margin-top:10.0pt;margin-right:64.05pt;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-21.25pt;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin:0cm;margin-bottom:.0001pt; text-indent:0cm;line-height:normal}tr.au{height:4.0pt}td.aw{width:272.55pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}td.av{width:216.15pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}td.as{width:251.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.cr{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-19.25pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt}td.ar{width:237.25pt;padding:0cm 5.4pt 0cm 5.4pt} td.aq{border:none}p.cs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}span.ao{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}span.ct{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cu{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph}p.cv{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify; text-justify:inter-ideograph}p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:8.0pt;margin-right:0cm;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph; line-height:normal;text-autospace:none} /**/
RNS Number : 3806S
Genedrive PLC
06 November 2019
 

genedrive plc

("genedrive" or the "Company")

 

Notice of AGM, Posting of Annual Report and Change of Auditors

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that copies of its 2019 Annual Report and Accounts and Notice of the 2019 Annual General Meeting ("AGM") have been posted to shareholders and are available on the Group's  website  http://www.genedriveplc.com/investor-relations/company-reports.php

  

The Company's AGM will be held at 12:00pm on 27 November 2019 at 46 Grafton Street, Manchester M13 9XX.

 

The Company also announces the intention to propose to shareholders, for approval at the Company's forthcoming AGM, the appointment of RSM UK Audit LLP as its auditor for the year ending 30 June 2020.

 

This decision follows a competitive tender process which has been overseen by the Audit and Risk Committee. PwC LLP (PwC), the Company's current auditor, undertook and completed the audit for the year ended 30 June 2019. PwC has confirmed to the Company that it is not aware of any circumstances connected with its termination as auditor that it considers should be brought to the attention of the Board, creditors or shareholders of the Company.

 

 

 

For further details please contact:                                                       

genedrive plc

www.genedriveplc.com

David Budd: CEO / Matthew Fowler: CFO

+44 (0)161 989 0245



Peel Hunt LLP

+44 (0)20 7418 8900

James Steel / Oliver Jackson




Stanford Capital Partners Limited

+44 (0)20 3815 8880

Patrick Claridge / John Howes




Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

 

Notes to Editors

 

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID kit has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. The Company has assays on market for the detection of certain biological targets and has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOABABRTMBBMBPL

Quick facts: Genedrive PLC

Price: 21.5

Market: AIM
Market Cap: £7.5 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Genedrive reports 'high clinical accuracy' for its AIHL...

Headlines from Proactive UK newsroom. Genedrive (LON:GDR) has scored 100% diagnostic sensitivity and 100% specificity in a test of its assay kit to identify babies at risk of hearing loss from the use of antibiotic gentamicin. The clinical study was based on 303 samples. Gold miner...

1 week, 4 days ago

RNS

Holding(s) in Company

3 days, 4 hours ago

Holding(s) in Company

3 days, 12 hours ago

Additional Listing

1 week, 2 days ago

Result of AGM

2 weeks, 3 days ago

Director/PDMR Shareholding

3 weeks, 1 day ago

Holding(s) in Company

on 22/10/19